<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>NO plays critical roles in vascular function </plain></SENT>
<SENT sid="1" pm="."><plain>We show that modulation of the eNOS serine 1179 (S1179) phosphorylation site affects vascular reactivity and determines <z:hpo ids='HP_0001297'>stroke</z:hpo> size in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>Transgenic mice expressing only a phosphomimetic (S1179D) form of eNOS show greater vascular reactivity, develop less severe <z:hpo ids='HP_0001297'>strokes</z:hpo>, and have improved cerebral blood flow in a middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model than mice expressing an unphosphorylatable (S1179A) form </plain></SENT>
<SENT sid="3" pm="."><plain>These results provide a molecular mechanism by which multiple diverse cardiovascular risks, such as <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001513'>obesity</z:hpo>, may be centrally integrated by eNOS phosphorylation in vivo to influence blood flow and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>They also demonstrate the in vivo relevance of posttranslational modification of eNOS in vascular function </plain></SENT>
</text></document>